SwePub
Sök i LIBRIS databas

  Utökad sökning

L773:0741 238X OR L773:1865 8652
 

Sökning: L773:0741 238X OR L773:1865 8652 > Model-Informed Supp...

Model-Informed Support of Dose Selection for Prophylactic Treatment with Dalcinonacog Alfa in Adult and Paediatric Hemophilia B Patients

Faraj, Alan (författare)
Uppsala universitet,Institutionen för farmaceutisk biovetenskap
Le Moan, Natacha (författare)
Catalyst Biosci, South San Francisco, CA USA.
Gorina, Eduard (författare)
Catalyst Biosci, South San Francisco, CA USA.
visa fler...
Blouse, Grant E. E. (författare)
Catalyst Biosci, South San Francisco, CA USA.
Knudsen, Tom (författare)
Catalyst Biosci, South San Francisco, CA USA.
Simonsson, Ulrika S. H., Professor (författare)
Uppsala universitet,Institutionen för farmaceutisk biovetenskap
visa färre...
 (creator_code:org_t)
Springer Nature, 2023
2023
Engelska.
Ingår i: Advances in Therapy. - : Springer Nature. - 0741-238X .- 1865-8652. ; 40:9, s. 3739-3750
  • Tidskriftsartikel (refereegranskat)
Abstract Ämnesord
Stäng  
  • IntroductionDalcinonacog alfa (DalcA), a novel subcutaneously administered recombinant human factor IX (FIX) variant is being developed for adult and paediatric patients with hemophilia B (HB). DalcA has been shown to raise FIX to clinically meaningful levels in adults with HB. This work aimed to support dosing regimen selection in adults and perform first-in-paediatric dose extrapolations using a model-based pharmacokinetic (PK) approach.MethodsA population PK model was built using adult data from two clinical trials (NCT03186677, NCT03995784). With allometry in the model, clinical trial simulations were performed to study alternative dosing regimens in adults and children. Steady-state trough levels and the time-to-reach target were derived to inform dose selection.ResultsAlmost 90% of the adults were predicted to achieve desirable FIX levels, i.e. 10% FIX activity, following daily 100 IU/kg dosing, with 90% of the subjects reaching target within 1.6-7.1 days. No every-other-day regimen met the target. A dose of 125 IU/kg resulted in adequate FIX levels down to 6 years, whereas a 150 IU/kg dose was needed below 6 down to 2 years of age. For subjects down to 6 years that did not reach target with 125 IU/kg, a dose escalation to 150 IU/kg was appropriate. The children below 6 to 2 years were shown to need a dose escalation to 200 IU/kg if 150 IU/kg given daily was insufficient.ConclusionThis study supported the adult dose selection for DalcA in the presence of sparse data and enabled first-in-paediatric dose selection to achieve FIX levels that reduce risk of spontaneous bleeds.

Ämnesord

MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin -- Hematologi (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine -- Hematology (hsv//eng)

Nyckelord

Dalcinonacog alfa
Population pharmacokinetics
Hemophilia B
MID3
Dose selection

Publikations- och innehållstyp

ref (ämneskategori)
art (ämneskategori)

Hitta via bibliotek

Till lärosätets databas

Sök utanför SwePub

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy